Back to top

Quince Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer analyst Mazahir Alimohamed initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $82 price target The company’...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Quince Therapeutics, Inc. (QNCX)